Sofwave to Participate in the Jefferies Virtual Private MedTech Summit
September 25, 2024 08:00 ET
|
SofWave Medical, Ltd.
SAN CLEMENTE, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, today announced...
Foresight Signs Strategic Agreement with Leading AI Company to Commercialize Advanced Solutions for Smart Transportation
September 24, 2024 08:35 ET
|
Foresight Autonomous Holdings Ltd.
CDG, a $IB annual revenue corporation, will leverage its expertise to lead the marketing and sales efforts of the intelligent traffic systems in mainland China Ness Ziona, Israel, Sept. 24, 2024 ...
Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis
September 24, 2024 07:00 ET
|
Can-Fite BioPharma Ltd.
The agreement has been signed upon successful conclusion of a clinical study in dogs with osteoarthritis RAMAT GAN, Israel, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE...
UMH PROPERTIES, INC. WILL HOST THIRD QUARTER 2024 FINANCIAL RESULTS WEBCAST AND CONFERENCE CALL
September 23, 2024 14:45 ET
|
UMH Properties, Inc.
FREEHOLD, NJ, Sept. 23, 2024 (GLOBE NEWSWIRE) -- UMH Properties, Inc. (NYSE:UMH) (TASE:UMH), a real estate investment trust (REIT) specializing in manufactured home communities, announced that it...
Kamada Announces Expansion of Plasma Collection Operations in Texas with the Opening of New Site in Houston
September 23, 2024 07:00 ET
|
Kamada Ltd.
New Plasma Collection Center in Houston Now Open, with Planned Annual Collection Capacity of Approximately 50,000 Liters and an Estimated Annual Revenue Contribution of $8 Million to $10 Million at...
Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia
September 23, 2024 01:00 ET
|
Teva Pharmaceutical Industries Ltd
RIM-TD open-label extension (OLE) study showed long-term improvement of Tardive Dyskinesia (TD) symptoms from treatment with deutetrabenazine over three years in European patients1 TD is an...
Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia
September 21, 2024 04:15 ET
|
Teva Pharmaceutical Industries Ltd
As a leader in neuroscience, Teva is committed to researching new treatment innovations that may help address unmet needs in treating schizophrenia, including TEV-‘749Currently, there is no...
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
September 21, 2024 04:10 ET
|
Teva Pharmaceutical Industries Ltd
As a leader in neuroscience, Teva remains committed to helping address unmet needs in the treatment of schizophrenia through scientific and clinical advances that support optimal treatment options and...
Nayax to Partner With Five Star's Feeding the Future Charitable Golf Tournament on September 23, 2024
September 19, 2024 07:00 ET
|
Nayax Ltd.
Nayax is proud to be a sponsor of Feeding the Future’s Golf Classic for the fourth consecutive year.
SaverOne Announces New Pilot with Malta Public Transport Company
September 18, 2024 08:00 ET
|
SaverOne 2014 Ltd.
Petah Tikvah, Israel, Sept. 18, 2024 (GLOBE NEWSWIRE) -- SaverOne 2014 Ltd. (Nasdaq: SVRE, TASE: SVRE), a technology company that develops and sells advanced transportation safety solutions, today...